Resultado de búsqueda
Hace 2 días · At a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62% compared to KEYTRUDA alone in these patients The 2.5-year recurrence-free survival rate of mRNA-4157 (V940) in combination with KEYTRUDA was 74.8% as compared to 55.6% for KEYTRUDA ...
Hace 5 días · Moderna expects to have mRESVIA available for eligible populations in the U.S. by the 2024/2025 respiratory virus season. Moderna has filed for mRNA-1345 approval with regulators in multiple markets around the world. About mRESVIA ® (Respiratory Syncytial Virus Vaccine)
10 de may. de 2024 · Discover real-time Moderna, Inc. Common Stock (MRNA) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Stay ahead with Nasdaq.
22 de may. de 2024 · Comité de Moléculas Nuevas de Cofepris emite opinión favorable a vacuna anti-COVID Spikevax monovalente de Moderna Tx. Comunicado de prensa 113/2023. Comisión Federal para la Protección contra Riesgos Sanitarios | 17 de octubre de 2023.
Hace 5 días · Stock analysis for Moderna Inc (MRNA:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
24 de may. de 2024 · See the latest Moderna stock price and MRNA stock rating, related news, valuation, dividends and more to help you make your investing decisions.
22 de may. de 2024 · Comité de Moléculas Nuevas de Cofepris emite opinión favorable a vacuna anti-COVID Spikevax® monovalente de Moderna Tx. 17 de octubre de 2023. https://bit.ly/3sKjfoG . Avanza proceso de obtención de registros sanitarios para vacunas contra COVID-19. 3 de noviembre de 2023. https://bit.ly/3uuUzB9
